---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002750"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T20:39:39.976356+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma issues pre-funded warrant to Cytovance for 326,251 shares as service consideration

## Summary
- Issued pre-funded warrant to purchase up to 326,251 shares of common stock at $0.0001 per share.
- Aggregate exercise price of $846,562.50 was pre-funded via services rendered by Cytovance Biologics.
- Warrant is immediately exercisable with a beneficial ownership limitation; no cash received.
- Issued without registration under Section 4(a)(2) of Securities Act as a private transaction.

## SEC filing metadata
- accession: 0001641172-25-002750
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000164117225002750/0001641172-25-002750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000164117225002750/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002750
- JSON: https://secwatch.observer/filing/0001641172-25-002750.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.